芬戈莫德可促进初级T细胞应答并减少佐剂需求
该研究在小鼠中探索用低剂量TLR佐剂蛋白疫苗联合S1P类似物芬戈莫德进行T细胞 priming。结果显示在特定时间于同一接种部位给予一次低剂量芬戈莫德后,低剂量佐剂疫苗可诱导与常规剂量佐剂疫苗相当的抗原特异性CD8+ T细胞初级应答的幅度和功能。联合接种还增强cDC1在淋巴结内积聚并减少注射部位皮肤炎症。
要点
- 芬戈莫德联合低剂量佐剂疫苗可达到常规剂量佐剂的CD8+ T细胞应答水平
- 联合方案模拟常规剂量佐剂疫苗的抗原特异性CD8+ T细胞扩增动力学
- 联合接种增强淋巴结cDC1积聚并减轻注射部位皮肤炎症
核心结论
- 芬戈莫德作为非佐剂性药物可促进抗原特异性T细胞 priming,并减少佐剂需求与不良反应。
研究设计与样本
- 研究在小鼠中使用含低剂量TLR佐剂的蛋白疫苗(LDAV)与常规剂量佐剂疫苗(RDAV)进行比较。
- 在特定时间于同一接种部位后给予一次低剂量S1P类似物芬戈莫德,并进行时间进程与淋巴结细胞分析。
主要发现
- 低剂量佐剂疫苗联合芬戈莫德诱导的初级应答在幅度和功能上达到常规剂量佐剂疫苗水平。
- 联合方案模拟常规剂量佐剂疫苗诱导的抗原特异性CD8+ T细胞扩增动力学。
- 联合接种小鼠淋巴结内cDC1积聚明显增强,尽管佐剂用量减少。
- 联合接种注射部位皮肤炎症轻微。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The CD8+ T-cell response is an essential part of the adaptive immunity. Adjuvants are routinely required for priming of T cells against antigens encountered in lymph nodes (LNs) to generate antigen-specific immunity but may concomitantly trigger unexpected inflammatory responses. Sphingosine-1-phosphate (S1P) induces transient desensitization of S1P receptors on LN T cells and temporarily blocks their egress, leading to prolonged intranodal retention that allows effective immunosurveillance and increases the chance of priming. In light of the regulatory role of S1P in T-cell migration, we here develop a strategic approach to the T-cell priming with protein vaccine containing low-dose TLR-based adjuvants (LDAV) to induce antigen-specific CD8+ T cell responses as efficiently as using regular dose adjuvants in vaccine (RDAV). We found that when combined with one low dose of the S1P analog fingolimod administered into the same vaccination site posteriorly at a specific time, LDAV can elicit a primary response that reaches the level of that induced by RDAV with respect to the response magnitude and functionality. Time-course studies indicate that LDAV and fingolimod in combination act to mimic the expansion kinetics of RDAV-primed antigen-specific CD8+ T cells. Further, intranodal accumulation of cDC1 is markedly enhanced in mice receiving the combination vaccination despite the decrease in adjuvant use. Of particular note is the marginal cutaneous inflammation at the injection site, indicating an added benefit of using fingolimod. Therefore, fingolimod as a nonadjuvant agent essentially facilitates antigen-specific T-cell priming with reduced need of adjuvants and minimized adverse reactions.
引用
- Gao C, Zhuang X, Zhang L, et al. Fingolimod can act as a facilitator to establish the primary T-cell response with reduced need of adjuvants. Vaccine. 2018. PMID: 30392766. doi:10.1016/j.vaccine.2018.10.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。